|Videos|August 26, 2021
Part 1: Practical Considerations For Venetoclax in AML
Alexandra S. Wolff, PharmD, BCOP, highlights considerations for optimal use of venetoclax in patients with AML, such as tumor lysis syndrome prophylaxis.
Advertisement
Episodes in this series
Advertisement
Related to this article
Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Data Reshapes Nonstatin Lipid Therapy Choices
2
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
3
Etentamig Reduces Risk of Progression or Death by 60% in Relapsed/Refractory Multiple Myeloma
4
From Evidence to Execution: Pharmacists Navigate MRA Selection and Access in HFpEF and HFmrEF
5